Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV. Atkinson V, et al. Among authors: soriano v. Melanoma Res. 2020 Jun;30(3):261-267. doi: 10.1097/CMR.0000000000000654. Melanoma Res. 2020. PMID: 31895752
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Berrocal A, Arance A, Lopez Martin JA, Soriano V, Muñoz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S; Spanish Melanoma Group. Berrocal A, et al. Among authors: soriano v. Melanoma Res. 2014 Dec;24(6):577-83. doi: 10.1097/CMR.0000000000000108. Melanoma Res. 2014. PMID: 25046550 Free PMC article.
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S. Espinosa E, et al. Among authors: soriano v. Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254. Melanoma Res. 2016. PMID: 26958991 Free PMC article.
Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.
Martín Algarra S, Soriano V, Fernández-Morales L, Berciano-Guerrero MÁ, Mujika K, Manzano JL, Puértolas Hernández T, Soria A, Rodríguez-Abreu D, Espinosa Arranz E, Medina Martínez J, Márquez-Rodas I, Rubió-Casadevall J, Ortega ME, Jurado García JM, Lecumberri Biurrun MJ, Palacio I, Rodríguez de la Borbolla Artacho M, Altozano JP, Castellón Rubio VE, García A, Luna P, Ballesteros A, Fernández O, López Martín JA, Berrocal A, Arance A. Martín Algarra S, et al. Among authors: soriano v. Medicine (Baltimore). 2017 Dec;96(52):e9523. doi: 10.1097/MD.0000000000009523. Medicine (Baltimore). 2017. PMID: 29384960 Free PMC article.
Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
Gonzalez-Cao M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, Molina-Vila MÁ, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Spanish Melanoma Group. Gonzalez-Cao M, et al. Among authors: soriano v. Melanoma Res. 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432. Melanoma Res. 2018. PMID: 29481492
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
Plummer R, Lorigan P, Brown E, Zaucha R, Moiseyenko V, Demidov L, Soriano V, Chmielowska E, Andrés R, Kudryavtseva G, Kahatt C, Szyldergemajn S, Extremera S, de Miguel B, Cullell-Young M, Calvert H. Plummer R, et al. Among authors: soriano v. Br J Cancer. 2013 Sep 17;109(6):1451-9. doi: 10.1038/bjc.2013.477. Epub 2013 Aug 29. Br J Cancer. 2013. PMID: 23989947 Free PMC article. Clinical Trial.
TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ, Rachakonda S, García-Casado Z, Srinivas N, Skorokhod A, Requena C, Soriano V, Kumar R, Nagore E. Andrés-Lencina JJ, et al. Among authors: soriano v. Int J Cancer. 2019 Mar 1;144(5):1027-1036. doi: 10.1002/ijc.31780. Epub 2018 Oct 4. Int J Cancer. 2019. PMID: 30070694
Dusky erythema secondary to anti-MEK therapy.
Bancalari B, Algarra MA, Llombart B, Nagore E, Soriano V, Sanmartín O, Requena C. Bancalari B, et al. Among authors: soriano v. Melanoma Res. 2019 Aug;29(4):449-451. doi: 10.1097/CMR.0000000000000602. Melanoma Res. 2019. PMID: 31246729 No abstract available.
1,490 results